Impact of cellular folate status and epidermal growth factor receptor expression on BCRP/ABCG2-mediated resistance to gefitinib and erlotinib by Lemos, C et al.
Impact of cellular folate status and epidermal growth factor
receptor expression on BCRP/ABCG2-mediated resistance to
gefitinib and erlotinib
C Lemos*,1,2, I Kathmann
2, E Giovannetti
2, C Calhau
1, G Jansen
3 and GJ Peters
2
1Department of Biochemistry (U38-FCT), Faculty of Medicine, University of Porto, Porto 4200-319, Portugal;
2Department of Medical Oncology, VU
University Medical Center, Amsterdam 1081 HV, The Netherlands;
3Department of Rheumatology, VU University Medical Center, Amsterdam 1081 HV,
The Netherlands
The effect of folate status on breast cancer resistance protein (BCRP)-mediated drug resistance to epidermal growth factor receptor
(EGFR)-targeted drugs, such as gefitinib and erlotinib, was investigated in two human colon cancer cell lines, WiDr and Caco-2, of
which the latter displayed greater sensitivity to these drugs due to high EGFR expression. Caco-2 LF/LV cells, growing under low-
folate (LF) conditions, showed increased BCRP protein expression compared with the high-folate (HF) counterpart, which was
associated with 1.8-fold resistance to gefitinib. Of note, the BCRP-specific inhibitor Ko143 completely reverted this phenotype. WiDr
LF cells also showed slightly increased BCRP expression compared with the HF cells, but no differences in gefitinib sensitivity were
observed. Both Caco-2 LF/LV and WiDr LF cells showed 2.4- and 2.3-fold resistance to erlotinib, respectively, compared with their
HF counterparts, which mechanistically seemed BCRP unrelated, as Ko143 had no effect on erlotinib activity. In conclusion, our data
suggest that in EGFR-expressing Caco-2 cells, BCRP is one of the determinants of gefitinib resistance but not of erlotinib resistance.
Beyond this, folate depletion can provoke an additional decrease in gefitinib and erlotinib activity by mechanisms dependent or
independent of BCRP modulation.
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The epidermal growth factor receptor (EGFR) signalling pathway
has an important function in tumour development and progres-
sion. In human solid tumours, receptor overactivation and/or
dysregulation, and concomitant activation of downstream routes,
promotes cell proliferation and survival, angiogenesis, metastatic
spread and inhibition of apoptosis. Thus, targeting the EGFR has
become an important approach in cancer therapy (Ciardiello and
Tortora, 2001; Mendelsohn and Baselga, 2003). Among the several
potential strategies for targeting this receptor, the development of
low-molecular-weight EGFR tyrosine kinase inhibitors (TKIs),
such as gefitinib (Iressa) and erlotinib (Tarceva), has revealed
promising results (Ciardiello and Tortora, 2001; Janmaat and
Giaccone, 2003; Mendelsohn and Baselga, 2003). These orally
active compounds are reversible competitors with ATP for binding
to the intracellular protein tyrosine kinase domain of the receptor,
thereby blocking receptor activation and downstream signalling
(Ciardiello and Tortora, 2001; Janmaat and Giaccone, 2003;
Mendelsohn and Baselga, 2003; Steeghs et al, 2007).
The breast cancer resistance protein (BCRP/ABCG2) is a
member of the major family of ATP-binding cassette (ABC)
transporters, which also includes P-glycoprotein (ABCB1) and the
multidrug resistance protein (ABCC) family (Borst and Elferink,
2002). Similar to other members of the family, BCRP over-
expression is commonly associated with multidrug resistance in
cancer cells, as it has the ability to extrude a variety of anticancer
drugs that appear to be structurally and mechanistically unrelated.
The spectrum of anticancer drugs effluxed by BCRP includes
mitoxantrone, camptothecins, anthracyclines, flavopiridol and
antifolates (Assaraf, 2006; Robey et al, 2007).
Some recent studies have shown that gefitinib is an inhibitor
and a substrate for BCRP (Elkind et al, 2005; Nakamura et al,
2005). Nonetheless, contradictory results have been reported.
Nakamura et al (2005) reported that gefitinib was able to reverse
drug resistance through inhibition of drug efflux in three
multidrug-resistant cancer cell lines overexpressing BCRP. How-
ever, the same authors demonstrated that gefitinib was not a
substrate for BCRP. In contrast, Elkind et al (2005) showed that
BCRP can actively pump gefitinib out of A431 cells expressing
wild-type BCRP. The apparent discrepancy between these studies
is, most likely, due to the selected concentrations of gefitinib used.
As it was recently shown by Li et al (2007), gefitinib is transported
by BCRP at low concentrations (eg, 0.1 and 1mM); however, at
higher drug concentration (eg, 10mM) gefitinib is no longer
transported by BCRP and it exhibits an inhibitory effect on the
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stransporter (Li et al, 2007). Several other TKIs were shown to
interact with BCRP, such as canertinib (Erlichman et al, 2001),
imatinib (Burger et al, 2004; Houghton et al, 2004; Jordanides et al,
2006; Brendel et al, 2007) and nilotinib (Brendel et al, 2007). Also
for erlotinib some interactions with BCRP have been described.
A preliminary study suggested that erlotinib is also a substrate of
BCRP (Marchetti et al, 2008). In fact, it has been shown that BCRP
is able to transport erlotinib at low concentrations (0.1–1mM)
(Li et al, 2007). In addition, it was shown that erlotinib at higher
drug concentrations is a BCRP inhibitor (Shi et al, 2007). It has
been hypothesised that the phosphorylation of EGFR may activate
Akt phosphorylation, which may subsequently affect the function
and localisation of BCRP (Lemos et al, 2008a). Also single
nucleotide polymorphisms (SNPs) in the ABCG2 gene might affect
the protein expression and function of the transporter (Yanase
et al, 2006). In particular, the BCRP C421A SNP has been
associated with decreased levels of protein expression and drug
resistance (Imai et al, 2002), which might have important impact
in the efficacy/toxicity of some BCRP drug substrates such as
gefitinib (Cusatis et al, 2006; Li et al, 2007).
Apart from anticancer drugs, BCRP has also the ability to
transport natural compounds such as folates (Chen et al, 2003). In
this context, recent studies have shown that folate status might
have significant implications in functional activity of BCRP
(Ifergan et al, 2004; Lemos et al, 2008b). From this perspective,
the aim of this study was to investigate the effect of cellular folate
status on BCRP-mediated resistance to the EGFR TKIs gefitinib
and erlotinib.
MATERIALS AND METHODS
Chemicals
Folic acid (FA), leucovorin (LV) and sulphorhodamine B (SRB)
were obtained from Sigma (St Louis, MO, USA). Protease inhibitor
cocktail was obtained from Roche Diagnostics (Mannheim,
Germany). Ko143 was generously provided by Professor
G JK o o m e n ,U n i v e r s i t yo fA m s t e r d a m ,A m s t e r d a m ,t h eN e t h e r l a n d s .
Erlotinib was a gift from Roche Pharmaceuticals (Mannheim,
Germany) and gefitinib from AstraZeneca (Macclesfield, UK).
Cell culture
The human colon adenocarcinoma cell lines Caco-2 and WiDr,
with constitutive BCRP expression, were cultured in RPMI 1640
medium (Cambrex Bioscience, Verviers, Belgium) containing
2.3mM FA (HF, high folate), supplemented with 10% fetal calf
serum (FCS; Greiner Bio-One, Frickenhausen, Germany) and
20mM of HEPES (Cambrex Bioscience). Caco-2 LF/LV, Caco-2
LF/FA and WiDr LF, originally isolated by gradual deprivation of
folates from the growth medium (van der Wilt et al, 1995; Lemos
et al, 2008b), were cultured in FA-free RPMI 1640 medium
(Invitrogen, Grand Island, NY, USA) supplemented with 10%
dialysed FCS (Invitrogen), 20mM of HEPES, and 1nM LV
(Caco-2 LF/LV), 1nM FA (Caco-2 LF/FA) or 2.5nM LV (WiDr LF).
The human breast cancer cell line with acquired resistance to
mitoxantrone (MR), MCF-7/MR (Taylor et al, 1991), was cultured
in RPMI 1640 medium containing 2.3mM FA, supplemented with
5% FCS, 2mML -glutamine, penicillin, streptomycin and was
bimonthly pulsed with 100nM of MR.
Growth inhibition studies
Growth inhibition by gefitinib and erlotinib was determined with
the SRB assay as described previously (Keepers et al, 1991).
Shortly, cells were seeded in 100ml of medium, in triplicate, in 96-
well flat bottom plates at a density of 8000 (Caco-2) or 5000 (WiDr)
cells per well. Cells were allowed to attach for 24h at 371C.
Attached cells were then exposed to various concentrations of drug
(5–50000nM of gefitinib or erlotinib) in 100ml of medium. The
BCRP-specific inhibitor Ko143 (Allen et al, 2002) was added
15min before the drugs and it was present during the next 72h at a
concentration of 200nM. After a drug exposure time of 72h, cells
were fixed with trichloroacetic acid, stained with SRB protein dye
and optical density (OD) was measured at 492nm. Control wells,
containing cells with culture medium but no drugs, were cultured
for 1 day (day 0) followed by an additional 72h and were used to
determine the control cell growth at 72h compared to the initial
number of cells (day 0 value); wells with culture medium only were
used as blanks. To distinguish between cell growth inhibition and
cell kill, we corrected the OD after 72h for the mean OD observed
for the control wells at the day of drug addition (day 0 value). For
each experiment the results were plotted in an Excel graph and the
IC50 value was determined. The IC50, defined as the drug
concentration that corresponds to a reduction of cellular growth
by 50% when compared with values of untreated control cells, was
used as a measure of resistance.
Western blot analysis of BCRP and EGFR expression
Total lysates were prepared in buffer containing 50mM Tris (pH
7.6), 20% (v/v) glycerol, 5mM DTT, 0.5% (v/v) NP-40 and 4.0%
(v/v) of a protease inhibitor cocktail. Lysates were sonicated three
times for 5s with 30s interval (MSE Soniprep 150, 41C, amplitude
6–7) and centrifuged at 13000r.p.m. for 10min at 41C. The protein-
containing supernatant was collected and protein content was
determined using the Bio-Rad protein assay. In each lane of a Bio-
Rad mini-gel system (Bio-Rad, Hemel Hempstead, UK) 1–40mgo f
proteins was loaded. For detection of BCRP a monoclonal rat anti-
BCRP antibody (BXP-53; 1:200; 1.25mgml
 1)( J o n k e ret al, 2002)
was used (kindly provided by Dr GL Scheffer, VU University
Medical Center, Amsterdam, the Netherlands). For detection of
phospho-Akt (pAkt), we used a rabbit anti-pAkt (Ser 473) antibody
(Cell Signaling Technology, Danvers, MA, USA; 1:500) and for
detection of EGFR, we used a rabbit anti-EGFR antibody (Cell
Signaling Technology; 1:1000). As secondary antibodies, horse-
radish peroxidase-conjugated rabbit anti-rat (DakoCytomation,
Glostrup, Denmark; 1:2000) and donkey anti-rabbit (GE Healthcare,
Chalfont St Giles, UK; 1:2000) were used. As a loading control,
expression of b-actin was determined using an antibody against
b-actin (clone C4 from Chemicon International, Temecula, CA, USA;
1:10000; 0.01mgml
 1).
Real-time LC-PCR
Total RNA was isolated from Caco-2 and WiDr cells using the
RNeasy Plus Mini Kit (Qiagen, Hilden, Germany) according to
manufacturer’s instructions. RNA was reverse-transcribed to
cDNA using random hexamers as previously described (van der
Wilt et al, 2003).
Real-time PCR analysis was performed using the LightCycler
(LC) instrument (Roche Diagnostics, Penzberg, Germany)
and Hybridization Probes, essentially as described earlier
(Sigmond et al, 2004). All samples were tested by the LightCycler
FastStart DNA Master
PLUS HybProbe kit (Roche Diagnostics)
according to manufacturer’s recommendations. PCR reactions
were performed in duplicate using 5ml of cDNA, which was
added to 15ml of reaction mixture containing 4ml of LightCycler
FastStart DNA Master
PLUS HybProbe ‘Master Mix’ (previously
prepared by the addition of 10ml of ‘Enzyme’ to one vial of
‘Reaction Mix’), 4ml (BCRP) or 0.4ml( b-actin) of a mix containing
forward and reverse primers and probe, and water (PCR grade), in
a final volume of 20ml. The final concentration of each component
in a 20ml reaction mixture was as follows: 50mUml
 1 Taq
DNA polymerase, 200mM dNTPs and 1.5mM MgCl2. For BCRP,
forward primer, 50-AGATGGGTTTCCAAGCGTTCAT; reverse
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sprimer, 50-CCAGTCCCAGTACGACTGTGACA; and probe, 50-6FAM-
TGCTGGGTAATCCCCAGGCCTCTATAGC-TAMRA, were used at a
final concentration of 400 and 200nM, for primers and probe,
respectively. For b-actin, forward primer, 50-TCACCCACACTGTG
CCCATCTACGA; reverse primer, 50-CAGCGGAACCGCTCATTGCC
AATGG; and probe, 50-6FAM-ATGCCCTCCCCCATGCCATCCTGC
GT-TAMRA, were used at a final concentration of 200nM.T h e
primers and probes used were designed using LightCycler probe
design software (Roche Diagnostics).
The PCR program consisted of an initial denaturation step at
951C for 10min and 45 cycles of warming up until 951C
immediately followed by 15s at 601C. After the final cycle, the
capillaries were cooled for 30s at 401C.
Fluorescence curves were analysed with the LC software (version
LCS4 4.0.5.415). This software uses the second derivative
maximum method to calculate the fractional cycle numbers where
the fluorescence rises above background (crossing point, CP); that
is, the point at which the rate of change of fluorescence is fastest.
The expression of BCRP was quantified relative to b-actin. For
this purpose, standard calibration curves were made for both
targets by amplifying 5ml of various dilutions of cDNA from a pool
of three cell lines (CEM/7A, MCF-7/MR and SW1573 2R/120), as
described above. For the standard curves, CPs were plotted vs log
concentration for the standards. These standard curves were used
to estimate the concentration of each sample.
BCRP polymorphism
The rs2231142 polymorphism of ABCG2 was studied with TaqMan
probes-based assays using the ABI PRISM 7500 instrument
equipped with the Sequence Detection System version 2.0 software
(Applied Biosystems, Foster City, CA, USA). Forward and
reverse primers and probes (Applied Biosystems SNP Genotyping
Assays products) were obtained from Applied Biosystems
(C_15854163_70, TaqMan Drug Metabolism Genotyping Assays).
The PCR reactions were performed using 20ng of genomic DNA
diluted in 11.875ml DNAse-RNAse free water, 12.5ml of TaqMan
Universal PCR Master Mix, with AmpliTaq Gold and 0.625ml of the
assay mix (forward and reverse specific primers and the specific
probes), in concentrations optimised in preliminary reactions, in a
total volume of 25ml. After thermal cycling, the instrument
determined the allelic content of each sample in the plate by
reading the generated fluorescence. A substantial increase in VIC
fluorescence indicated homozygosity for wild-type allele, an
increase in FAM fluorescence signalled homozygosity for mutant
allele, whereas both fluorescence signals indicated heterozygosity.
Calculations and statistics
Arithmetic means are given with s.e.m. Statistical significance of
the difference between two groups was evaluated by Student’s
t-test. Differences were considered to be significant when Po0.05.
RESULTS
BCRP expression in Caco-2 and WiDr HF- and LF-adapted
cells
We recently described the adaptation of Caco-2 cells, usually
cultured in standard RPMI medium containing supraphysiological
concentrations of folates (HF), to low-folate (LF) conditions (1nM
of LV or FA), resulting in the sublines Caco-2 LF/LV and Caco-2
LF/FA (Lemos et al, 2008b). Here we show that these LF-adapted
cell lines had a 1.3–2.2-fold increase in the constitutive BCRP
protein expression along with 3- to 4-fold increase in the mRNA
levels (Figure 1A and B). Of note, despite the intracellular
localisation of BCRP in Caco-2 cells, the LF-adapted cell lines
displayed 4- to 6-fold resistance to a prototypical BCRP substrate
mitoxantrone, suggesting that BCRP is functionally active in these
cells (Lemos et al, 2008b). Another human colon cancer cell line
adapted to LF conditions, WiDr LF, displayed only a moderate
increase in the constitutive expression of BCRP protein and mRNA
levels (1.6-fold) compared with their HF counterpart, as revealed
by western blot and real-time LC-PCR (Figure 1A and B). Also in
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Figure 1 BCRP and pAkt expression in Caco-2 and WiDr HF- and LF-adapted cells and MCF-7/MR cells. (A) BCRP protein expression was determined
by western blot analysis in Caco-2 and WiDr HF- and LF-adapted cells and MCF-7/MR cells. Per lane 15mg (Caco-2), 30mg (WiDr) or 1mg (MCF-7/MR) of
protein was loaded. As a loading control, b-actin levels are indicated. (B) BCRP mRNA levels assessed by real-time LC-PCR were determined in Caco-2 and
WiDr HF- and LF-adapted cells. Shown are the ratios between BCRP and the housekeeping gene, b-actin, presented as percent (%) of the HF cells. Bars
represent the arithmetic means±s.e.m. of two independent experiments performed in duplicate. (C) pAkt protein expression was determined by western
blot analysis in Caco-2 and WiDr HF- and LF-adapted cells. Per lane 30mg of protein was loaded. As a loading control, b-actin levels are indicated. Breast
cancer resistance protein in Caco-2, data from Lemos et al (2008b).
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sWiDr LF cells, BCRP has a predominant intracellular localisation;
nonetheless, these cells were about twofold resistant to mito-
xantrone compared with their HF counterpart, suggesting that also
in these cells BCRP is functionally active (data not shown). In
contrast with the colon cancer cell lines, MCF-7/MR breast cancer
cells displayed overexpression of BCRP (Figure 1A), being
predominantly located in the plasma membrane (Lemos et al,
2008b). It has been reported that the Akt phosphorylation status
might affect the function and localisation of BCRP (Lemos et al,
2008a). Therefore, we investigated whether folate deprivation has
an impact on Akt phosphorylation. For both WiDr and Caco-2, the
levels of pAkt were similar in HF- and LF-adapted cells
(Figure 1C), suggesting that cellular folate status has no impact
in the phosphorylation status of Akt. Consistently Caco-2 and
WiDr HF- and LF-adapted cells displayed a similar intracellular
localisation of BCRP.
Cellular growth inhibition with gefitinib and erlotinib in
Caco-2, WiDr and MCF-7/MR cells
To investigate whether the different levels of BCRP expression in
the Caco-2 and WiDr HF- and LF-adapted cell lines would have an
impact in the anticancer efficacy of gefitinib and erlotinib, we
performed growth inhibition studies in these cells as well as in the
BCRP-overexpressing cell line MCF-7/MR. Caco-2 LF/LV cells
showed 1.8-fold resistance to gefitinib and 2.4-fold resistance to
erlotinib compared with their HF counterpart. Inhibition of BCRP
with its specific blocker Ko143 (Allen et al, 2002) completely
abrogated gefitinib resistance in Caco-2 LF/LV cells, but had
almost no effect on erlotinib sensitivity (Figures 2A and 3A). In
contrast, the Caco-2 LF/FA cell line displayed similar sensitivity to
gefitinib and only a moderate level of resistance (1.3-fold) to
erlotinib compared with the Caco-2 HF cells (Figures 2A and 3A).
Interestingly, Ko143 rendered Caco-2 LF/FA cells 1.9- and 1.5-fold
more sensitive to gefitinib and erlotinib, respectively (Figures 2A
and 3A). No differences on gefitinib sensitivity were observed
between the WiDr HF- and LF-adapted cell lines (Figure 2B). In
contrast, WiDr LF cells were 2.3-fold resistant to erlotinib
compared with their HF counterpart, a phenotype that was almost
unaffected by BCRP inhibition with Ko143 (Figure 3B). MCF-7/MR
cells were used in this study as control because they express high
levels of BCRP and are highly resistant to BCRP substrates such as
MR and methotrexate (Maliepaard et al, 2001; Ifergan et al, 2004).
Breast cancer resistance protein was functionally active in these
cells based on the observation that a BCRP-specific blocker, Ko143,
could reverse MR sensitivity by 64-fold (data not shown).
Nonetheless, BCRP inhibition by Ko143 induced only marginally
decreases in the IC50 values for both gefitinib and erlotinib in these
cells (Figures 2C and 3C).
EGFR protein expression in Caco-2, WiDr and MCF-7/MR
cells
Epidermal growth factor receptor protein expression is an
important determinant of gefitinib and erlotinib sensitivity.
Therefore, we investigated the expression levels of the receptor
in all cell lines. Caco-2 cells, both HF and LF, displayed high levels
of EGFR protein. In WiDr HF- and LF-adapted cells EGFR protein
expression was markedly lower than in Caco-2 cells. Epidermal
growth factor receptor was almost absent in MCF-7/MR cells
(Figure 4).
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Figure 2 Cellular growth inhibition by gefitinib of Caco-2 and WiDr HF- and LF-adapted cells and MCF-7/MR cells. Growth inhibition by gefitinib was
determined after 72h of drug exposure in Caco-2 (A) and WiDr (B) HF- and LF-adapted cells and MCF-7/MR (C) cells. The BCRP-specific inhibitor Ko143
was added 15min before the drug and it was present during the next 72h at a concentration of 200nM. Shown are the IC50 values, presented as arithmetic
means±s.e.m., of at least three independent experiments. *Po0.05 versus Caco-2 LF/LV–Ko143.
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sBCRP genotype in Caco-2, WiDr and MCF-7/MR cells
The BCRP C421A polymorphism was studied in Caco-2 and WiDr
HF- and LF-adapted cells as well as in MCF-7/MR. All cell lines
displayed the wild-type genotype (CC) (data not shown).
DISCUSSION
To study the impact of different levels of BCRP expression in the
anticancer activity of two EGFR TKIs, gefitinib and erlotinib, we
initially performed growth inhibition studies with these drugs in
Caco-2 and WiDr HF- and LF-adapted cell lines as well as in MCF-7/
MR cells, with MR-induced overexpression of BCRP (Maliepaard
et al, 2001). Caco-2 LF/LV cells, but not Caco-2 LF/FA, showed
1.8-fold resistance to gefitinib compared with the HF cells.
Blocking BCRP with its specific inhibitor Ko143 completely
reverted the gefitinib resistance in Caco-2 LF/LV cells, suggesting
that the resistance to gefitinib in these cells can be attributed to the
increased expression of BCRP. Considering the higher BCRP
expression in Caco-2 LF/FA over LF/LV cells, one would anticipate
that these cells would also reveal resistance to gefitinib compared
with the HF counterpart, but surprisingly this was not observed.
This result might be explained by the limited range of drug
concentrations (up to 1mM) within which BCRP is able to transport
gefitinib (Elkind et al, 2005; Li et al, 2007). Owing to the higher
expression of BCRP in Caco-2 LF/FA than in Caco-2 LF/LV cells,
we would anticipate also a higher IC50 value for gefitinib, most
likely above 1mM; however, at this concentration, gefitinib is no
longer a substrate for BCRP, but rather an inhibitor (Li et al, 2007).
Therefore, we hypothesise that gefitinib inhibits BCRP in Caco-2
LF/FA cells, thereby attenuating its expected levels of resistance in
these cells. A similar complex interaction between BCRP and
imatinib has been described by Nakanishi et al (2006) who showed
that imatinib itself could attenuate its resistance by suppressing
BCRP expression. Furthermore, Ko143 rendered Caco-2 LF/FA
cells about twofold more sensitive to gefitinib, suggesting that
BCRP does have a function in gefitinib sensitivity in these cells. In
WiDr cells, no difference on gefitinib sensitivity was observed
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Figure 3 Cellular growth inhibition by erlotinib of Caco-2 and WiDr HF- and LF-adapted cells and MCF-7/MR cells. Growth inhibition by erlotinib was
determined after 72h of drug exposure in Caco-2 (A) and WiDr (B) HF- and LF-adapted cells and MCF-7/MR (C) cells. The BCRP-specific inhibitor Ko143
was added 15min before the drug and was present during the next 72h at a concentration of 200nM. Shown are the IC50 values, presented as arithmetic
means±s.e.m., of at least three independent experiments. *Po0.05 versus HF cells.
#Po0.05 versus LF/FA cells–Ko143.
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Figure 4 Epidermal growth factor receptor expression in Caco-2 and
WiDr HF- and LF-adapted cells and MCF-7/MR cells. Epidermal growth
factor receptor protein expression was determined by western blot
analysis in Caco-2 and WiDr HF- and LF-adapted cells and MCF-7/MR cells.
Per lane 40mg of protein was loaded. As a loading control b-actin levels are
indicated.
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BCRP in the LF cells. Likewise, in MCF-7/MR cells, we did not
observe major differences in gefitinib sensitivity when growth
inhibition experiments were performed in the presence or absence
of the BCRP inhibitor Ko143. Thus, although our results with
Caco-2 cells strongly suggest that BCRP can actively extrude
gefitinib and mediate resistance to this drug, the data obtained
with WiDr and MCF-7/MR suggested that its function is highly
variable. To further explore the mechanistic basis for this, we first
investigated two parameters that could contribute to TKI
resistance: (1) EGFR levels and (2) BCRP SNPs that may have a
function in the observed TKI-resistant phenotypes. Interestingly,
our present results were in line with observation by Yanase et al
(2004) showing that when gefitinib-sensitive A431 lung cancer cells
were transduced with BCRP (A431/BCRP) they became markedly
resistant to gefitinib whereas BCRP transfection in gefitinib-
insensitive leukemic K562 (K562/BCRP) and P388 (P388/BCRP)
cells did not much further increase gefitinib resistance. This may
be attributed to the fact that A431 cells express high EGFR levels to
elicit high sensitivity, whereas K562 and P388 cells do not express
EGFR thereby conferring inherent resistance to gefitinib. Con-
sistent with this notion, we observed that Caco-2 cells displayed
much higher expression levels of EGFR than WiDr and MCF-7/MR
cells and thereby confer much greater sensitivity to gefitinib
(Figure 5). Thus, conceivably, BCRP can be a major determinant in
conferring gefitinib resistance in Caco-2 cells because they express
EGFR and are more sensitive to the drug. Most likely, this is
associated with the fact that gefitinib transport by BCRP is
concentration dependent. It has been shown that low concentra-
tions of gefitinib (o1mM) significantly activated BCRP-ATPase
activity in isolated membranes of BCRP-expressing mammalian
MCF-7/MX and A431 cells, whereas higher gefitinib concentrations
(41mM) had a markedly lower stimulatory effect (Elkind et al,
2005). Several SNPs in the ABCG2 gene have been described that
might have an important impact on BCRP protein expression and
function (Yanase et al, 2006). Imai et al (2002) showed that the
BCRP nonsynonymous SNP C421A was associated with markedly
decreased levels of BCRP protein expression and also low levels
of drug resistance. More recently, Cusatis et al (2006) reported
that this polymorphism was associated with the occurrence
of diarrhoea in patients receiving treatment with oral gefitinib.
The authors suggested that the reduced protein levels and altered
ATPase activity of the BCRP C421A variant might affect the oral
absorption and/or elimination pathways of gefitinib thereby
increasing the steady-state gefitinib plasma concentrations leading
to the diarrhoea. In this context, we investigated the possible
presence of this BCRP variant in the cell lines used in this study.
However, all cells displayed the wild-type genotype (CC),
suggesting that the discrepancy in our results could not be
attributed to the C421A BCRP variant.
Caco-2 LF/LV cells were 2.4-fold resistant to erlotinib, compared
with the HF cells. However, in this case, the BCRP-specific
inhibitor Ko143 was not able to revert erlotinib resistance,
suggesting that BCRP is not involved in erlotinib resistance in
these cells. Consistently, Ko143 had no significant effect on
erlotinib sensitivity in MCF-7/MR cells. In addition, WiDr LF cells
were also 2.3-fold resistant to erlotinib, compared with the HF
cells, and Ko143 had no effect on the resistant phenotype,
corroborating the hypothesis that erlotinib resistance in LF-
adapted cells is mediated by a mechanism independent of BCRP.
Given the fact that erlotinib has been described as a BCRP
substrate (Li et al, 2007), one could expect that this transporter
would be implicated in erlotinib resistance. However, similarly to
gefitinib, erlotinib is only transported by BCRP at low concentra-
tions (p1mM), which can explain our observations in WiDr and
MCF-7/MR cells, because these cells display IC50 values for this
drug above 5mM. In Caco-2 cells, showing a considerably higher
sensitivity to this drug, it is possible that the levels of BCRP
overexpression in the LF-adapted cells do not reach a threshold
that can confer erlotinib resistance. Of note, although Caco-2 LF/FA
cells, which express the highest levels of BCRP among the Caco-2
cell lines, displayed only a marginal increase in erlotinib resistance
compared with the HF counterpart, they became significantly more
sensitive to the drug in the presence of Ko143. Therefore, we might
envision a function for BCRP in erlotinib resistance, but its relative
contribution is dependent on different factors determining
intrinsic drug sensitivity of the cells and the levels of BCRP
expression.
There are several potential mechanisms of resistance to EGFR
inhibitors in tumour cells, including (1) target gene alterations
and/or target protein loss; (2) loss/inactivation of downstream
signalling molecules, activation of other tyrosine kinase receptor
systems that are not EGFR related such as the insulin-like growth
factor family of ligands and receptors; (3) activation of EGFR-
independent tumour-induced angiogenesis, independent activa-
tion of intracellular signalling pathways that function downstream
to the EGFR; and finally (4) molecular changes in cancer cells that
affect EGFR inhibitor uptake (Bianco et al, 2005). In the present
study, we investigated whether erlotinib resistance in the LF-
adapted cells could be associated with a decrease or loss of EGFR
protein. Western blot analysis revealed that in Caco-2 and WiDr
cells EGFR was similarly expressed in the HF and LF cells, thus
suggesting that erlotinib resistance is not mediated by a
suppression or loss of EGFR expression.
It has been previously shown that folate supplementation/
deprivation might have important therapeutic implications
for several anticancer drugs (Hooijberg et al, 2006). In this study,
we provide further proof for an impact of cellular folate status on
drug efficacy, in particular for the EGFR TKIs gefitinib and
erlotinib. Although the mechanism involved seems to differ for
both drugs, our data clearly suggest that higher folate concentra-
tions convey a beneficial impact in the activity of these TKIs.
This is in agreement with a previous report from our laboratory,
showing that folate supplementation triggered a reduced BCRP-
mediated MR resistance in Caco-2 cells (Lemos et al, 2008b).
Nonetheless, opposite effects have also been described (Ifergan
et al, 2004), suggesting that the relationship between folates and
drug resistance/efficacy, especially when associated with MDR-
transporters, is complex and warrants further investigation.
In conclusion, our data suggest that BCRP is a major
determinant of gefitinib resistance in Caco-2 cells with constitutively
high EGFR expression. Conversely, in cells being intrinsically
resistant to gefitinib due to low/absent expression of EGFR such as
WiDR and MCF-7/MR cells, BCRP does not confer additional
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Figure 5 Representative dose/effect plot of cellular growth inhibition by
gefitinib in Caco-2 and WiDr HF cells. The graph is representative of three
independent experiments. s.d. o20%.
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sresistance. Rather than for gefitinib, our data suggested that
BCRP is not a major determinant of erlotinib resistance in the cell
models used in this study. Finally, we showed that modulation of
extra/intracellular folate status might have an impact on gefitinib
and erlotinib activity by mechanisms (in)dependent of BCRP
functioning.
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